Drugs / Probio Tec BB12-Blend 30- IF
Trials 0
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05682807 Comparator | Jun 2022 → Jun 2024 | bronchopulmonary dysplasia | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT06422000 Comparator | Jun 2022 → Nov 2023 | necrotizing enterocolitis | Tanta University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Probio Tec BB12-Blend 30- IF* | “probiotics sachets supplementation orally, in the form of lyophilized lactic acid bacteria each Aluminium stick pack contains 100 mg ( Meyer et al., 2020) Probio Tec BB12-Blend...” NCT05682807 ↗1“probiotics sachets supplementation, in the form of lyophilized lactic acid bacteria each Aluminium stick pack contains 100 mg ( Meyer et al., 2020) Probio Tec BB12-Blend 30-...” NCT06422000 ↗ |
| Modality | Other / unclassified | “lyophilized lactic acid bacteria” NCT06422000 ↗ |
| Route | Oral | “probiotics sachets supplementation orally” NCT05682807 ↗ |